CoChat

Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapy

Chang, Jennie T., Staffa, Judy A., Parks, Mary, Green, Lanh · 2004 · Pharmacoepidemiology and Drug Safety
Cited by 152

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Context: Elevated total cholesterol (total‐C) and low‐density lipoprotein cholesterol (LDL‐C) levels are established risk factors for cardiovascular disease (CVD). HMG‐CoA reductase inhibitors (statins) are effective cholesterol‐lowering drugs that are commonly prescribed to treat this condition. These drugs are often combined with another class of drugs, fibric acid derivatives, to lower both cholesterol and triglyceride levels. Rhabdomyolysis is a known, rare serious side effect of statin monotherapy and of statin‐fibrate combination therapy. Objective: To examine Food and Drug Administration's (FDA's) postmarketing database for cases of rhabdomyolysis in relation to monotherapy and combination use and calculate reporting rates for this event. Design: Domestic cases of statin‐ and statin/gemfibrozil‐associated rhabdomyolysis were culled from FDA's database and reviewed. Rhabdomyolysis was defined by CPK ≥ 10 000 IU/L, myopathic signs and symptoms and clinical diagnosis of rhabdomyolysis. Reporting rates, consisting of number of reported cases/number of prescriptions for each drug, were then calculated to determine whether the reporting of rhabdomyolysis cases was commensurate with extent of use of each statin in the population. Setting: Cases were obtained from the FDA adverse event reporting system (AERS) database. Patients: NA. Main Outcome Measures: Number of rhabdomyolysis cases were evaluated, along with outcomes, such as renal failure, dialysis and death. Results: Of 866 total reported cases, 482 (56%) were associated with monotherapy and 384 (44%) related to combination therapy. More than 80% of reported cases for each drug resulted in hospitalization for renal failure and dialysis. 80 patients expired from events related directly to rhabdomyolysis. Reporting rates for all statins, except for cerivastatin, were similar and much lower than 1 per 100 000 prescriptions. The cerivastatin‐reporting rate was much higher at 4.24/100 000 prescriptions. Conclusions: Rhabdomyolysis is a rare, serious side effect of statin monotherapy and of statin‐fibrate combination therapy. Clinicians need to remain cognizant of this potential adverse event and discuss signs and symptoms of muscle toxicity with patients in order improve the benefits‐to‐risks of treating dyslipidemia with statins. Copyright © 2004 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pds.977

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

Metadata

Authors
Chang, J. T., Staffa, J. A., Parks, M., & Green, L.
Venue
Pharmacoepidemiology and Drug Safety
Publisher
Wiley
Published
2004-05-24
Volume
13
Issue
7
Pages
417-426
ISSN
  • 1053-8569 (ISSN-L)
  • 1099-1557
OpenAlex
W2102504779
Cited by
152
References
5
FWCI
16.96
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.